ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0867

NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation

Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)

Meeting: ACR Convergence 2025

Keywords: bone biology, Fracture, Inflammasome, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Rheumatoid Arthritis – Animal Models (0867–0872)

Session Type: Abstract Session

Session Time: 10:00AM-10:15AM

Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of inflammation, drives inflammatory processes that fundamentally accompany the pathogenesis of RA. However, the role of NLRP3 inflammasome in RA fracture healing remains unclear.

Methods: For in vivo analyses, we established tibial fractures in two murine RA models: TNF-transgenic (TNFTg) mice and collagen-induced arthritis (CIA). To address the contribution of NLRP3 inflammasome to fracture repair in RA, we generated TNFTg;NLRP3KO mice by deleting the NLRP3 gene in TNFTg mice. The effects of TNFα overexpression on osteogenic differentiation were assessed using mesenchymal progenitor cells (MPCs) with or without MCC950, a potent and specific inhibitor of the NLRP3 inflammasome. The role of MCC950 in RA fracture repair was investigated using CIA mice.

Results: TNFTg mice exhibited delayed fracture healing, characterized by decreased callus bone volume and reduced bone mechanical strength. The NLRP3 inflammasome was excessively activated in TNFTg mice, leading to elevated expression of NLRP3, IL-1β, and Caspase-1. Moreover, NLRP3 deficiency in TNFTg mice significantly mitigated the delayed fracture healing (Fig. 1). Mechanistically, TNFα overexpression suppressed osteogenic differentiation of MPCs through NLRP3 inflammasome activation. This process involves RhoA/Rac1-dependent NF-κB signaling that triggers inflammasome assembly, ultimately leading to IL-1β secretion. Notably, MCC950 administration significantly attenuated these pathological effects. Lastly, in vivo MCC950 treatment rescued the delayed fracture healing by reducing NLRP3 inflammasome activation and promoting bone formation in CIA mice (Fig. 2).

Conclusion: This study provides novel insights into the mechanisms underlying delayed fracture healing in RA and highlights the potential therapeutic benefits of targeting the NLRP3 inflammasome (Fig. 3).

Supporting image 1NLRP3 deficiency improves delayed fracture healing in TNFTg RA mice

Supporting image 2MCC950 treatment alleviated the delayed fracture healing in CIA mice

Supporting image 3Schematic representation of the NLRP3 inflammasome delaying fracture healing in RA mice through RhoA/Rac1‒IL-1β-mediated osteoblast differentiation


Disclosures: W. Sun: None; H. Wang: None.

To cite this abstract in AMA style:

Sun W, Wang H. NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/nlrp3-inflammasome-impairs-fracture-repair-in-rheumatoid-arthritis-through-rhoa-rac1-il1%ce%b2-axis-mediated-suppression-of-osteoblast-differentiation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nlrp3-inflammasome-impairs-fracture-repair-in-rheumatoid-arthritis-through-rhoa-rac1-il1%ce%b2-axis-mediated-suppression-of-osteoblast-differentiation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology